Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT01642004
First received: July 9, 2012
Last updated: March 16, 2016
Last verified: March 2016
  Purpose
The purpose of the study is to compare the overall survival of BMS-936558 as compared with Docetaxel in subjects with squamous cell non-small cell lung cancer (NSCLC), after failure of prior platinum-based chemotherapy.

Condition Intervention Phase
Squamous Cell Non-small Cell Lung Cancer
Biological: Nivolumab
Drug: Docetaxel
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint [ Time Frame: Randomization until 199 deaths, up to November 2014, approximately 25 months ] [ Designated as safety issue: No ]
    OS was defined as the time between the date of randomization and the date of death from any cause. Participants were censored at the date they were last known to be alive. Median OS time was calculated using Kaplan-Meier (KM) method. Hazard ratio (HR) and the corresponding Confidence Interval (CI) were estimated in a stratified Cox proportional hazards model for distribution of OS in each randomized arm. Interim analysis (Primary Endpoint) was planned to occur after at least 196 deaths, with the actual analysis occurring at 199 deaths.

  • Overall Survival (OS) Rate in All Randomized Participants [ Time Frame: Randomization to 18 months post-randomization, up to June 2015 ] [ Designated as safety issue: No ]
    The overall survival rate is the probability that a participant will be alive at 6, 12, and 18 months following randomization. Overall survival was defined as the time between the date of randomization and the date of death as a result of any cause. Survival rates were determined via Kaplan-Meier estimates.

  • Number of Deaths From Any Cause in All Randomized Participants at Primary Endpoint [ Time Frame: Randomization until 199 deaths, up to November 2014, approximately 25 months ] [ Designated as safety issue: No ]
    The number of participants who died from any cause was reported for each arm. Interim analysis (Primary Endpoint) was planned to occur after at least 196 deaths, with the actual analysis occurring at 199 deaths.


Secondary Outcome Measures:
  • Objective Response Rate (ORR) in All Randomized Participants at Primary Endpoint [ Time Frame: Randomization until 199 deaths, up to November 2014, approximately 25 months ] [ Designated as safety issue: No ]

    ORR was defined as the percentage of all randomized participants whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR). BOR was defined as the best investigator-assessed response designation, recorded between the date of randomization and the date of objectively documented progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) or the date of subsequent anti-cancer therapy (excluding on-treatment palliative radiotherapy of non-target bone lesions or Central Nervous System (CNS) lesions), whichever occurred first.

    CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. CIs were computed using the Clopper and Pearson method.


  • Time To Response (TTR) in Months for All Confirmed Responders at Primary Endpoint [ Time Frame: Randomization until confirmed response, up to November 2014, approximately 25 months ] [ Designated as safety issue: No ]
    Time to Response (TTR) for participants demonstrating a response (either CR or PR) was defined as the time from the date of randomization to the date of the first confirmed response. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters.

  • Duration of Objective Response (DOR) in Months for All Confirmed Responders at Primary Endpoint [ Time Frame: Date of confirmed response to date of documented tumor progression, up to November 2014, approximately 25 months ] [ Designated as safety issue: No ]

    DOR was defined as the time from the date of first confirmed response to the date of the first documented tumor progression (per RECIST v1.1), as determined by the investigator, or death due to any cause, whichever occurred first. DOR was evaluated only for confirmed responders (i.e. participants with confirmed CR or PR).

    CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters.

    Participants who neither progressed nor died were censored on the date of their last evaluable tumor assessment.


  • Progression-Free Survival (PFS) at Primary Endpoint [ Time Frame: Randomization to 12 months post-randomization, up to November 2014 ] [ Designated as safety issue: No ]
    PFS rate was defined as the probability that participants will experience no disease progression or death from any cause at a given time point following randomization. Progression was assessed by investigators according to RECIST v1.1. 95% CIs were estimated using the Kaplan-Meier method. Participants who did not progress or die were censored on the date of their last evaluable tumor assessment. Participants who started any subsequent anti-cancer therapy (including on-treatment palliative radiation therapy (RT) of non-target bone lesions or CNS lesions) without a prior reported progression were to be censored at the last evaluable tumor assessment prior to or on initiation of the subsequent anti-cancer therapy

  • Progression-Free Survival (PFS) Time in Months for All Randomized Participants at Primary Endpoint [ Time Frame: Randomization until 199 deaths, up to November 2014, approximately 25 months ] [ Designated as safety issue: No ]
    PFS was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the investigator per RECIST v1.1 criteria, or death due to any cause. Participants underwent radiographic tumor assessments every 6 weeks (+/- 5 days) from week 9 (+/- 5 days) for the first year on treatment, then every 12 weeks after the first year on treatment until documented disease progression. The PFS curves were estimated using KM method. Two-sided 95% CI for median PFS were computed by Brookmeyer and Crowley method (using log-log transformation). Participants who did not progress or die were censored on the date of their last evaluable tumor assessment. Participants who started any subsequent anti-cancer therapy (including on-treatment palliative RT of non-target bone lesions or CNS lesions) without a prior reported progression were to be censored at the last evaluable tumor assessment prior to or on initiation of the subsequent anti-cancer therapy.

  • Percentage of Participants Experiencing Disease-related Symptom Improvement by Week 12 [ Time Frame: Randomization to Week 12 ] [ Designated as safety issue: No ]
    Disease-related symptom improvement rate by Week 12 was defined as the percentage of randomized participants who had a 10 point or greater decrease from baseline in average symptom burden index score at any time between randomization and Week 12. The participant portion of the Lung Cancer Symptom Scale (LCSS) consisted of 6 symptom-specific questions that addressed cough, dyspnea, fatigue, pain, hemoptysis, and anorexia, plus 3 summary items on symptom distress, interference with activity level, and global health-related Quality of Life (QoL). The scores range from 0 to 100, with 0 representing the best possible score and 100 being the worst possible score. The average symptom burden index score at each assessment was defined as the mean of the 6 symptom-specific questions of the LCSS. 95% CIs were computed using Clopper-Pearson Method.

  • Overall Survival (OS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint [ Time Frame: Randomization until 199 deaths, up to November 2014, approximately 25 months ] [ Designated as safety issue: No ]
    OS was measured in months for all randomized participants grouped by their baseline PD-L1 expression level. PD-L1 expression was defined as the percent of disease tumor cells demonstrating plasma membrane PD-L1 staining of any intensity using an immunohistochemistry (IHC) assay. OS was defined as the time between the date of randomization and the date of death from any cause. Participants were censored at the date they were last known to be alive. Median OS time was calculated using Kaplan-Meier (KM) method. Interim analysis (Primary Endpoint) was planned to occur after at least 196 deaths, with the actual analysis occurring at 199 deaths.

  • Objective Response Rate (ORR) by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint [ Time Frame: Randomization until 199 deaths, up to November 2014, approximately 25 months ] [ Designated as safety issue: No ]
    ORR was reported for all randomized participants grouped by their baseline PD-L1 expression level. ORR was defined as the percentage of all randomized participants whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR). PD-L1 expression in participants was defined as the percent of disease tumor cells demonstrating plasma membrane PD-L1 staining of any intensity using an immunohistochemistry (IHC) assay. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. CIs were computed using the Clopper and Pearson method.

  • Progression Free Survival (PFS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants at Primary Endpoint [ Time Frame: Randomization until 199 deaths, up to November 2014, approximately 25 months ] [ Designated as safety issue: No ]
    PFS time was measured for all randomized participants grouped by their baseline PD-L1 expression levels. PFS was defined as the time from the date of randomization to the date of the first documented tumor progression as determined by the investigator per RECIST v1.1 criteria, or death due to any cause. The PFS curves were estimated using KM method. Participants who did not progress or die were censored on the date of their last evaluable tumor assessment. Participants who started subsequent anti-cancer therapy (including on-treatment palliative radiotherapy of non-target bone lesions or CNS lesions) without a prior reported progression were censored at the last evaluable tumor assessment prior to subsequent anti-cancer therapy. Interim analysis (Primary Endpoint) was planned to occur after at least 196 deaths, with the actual analysis occurring at 199 deaths.


Other Outcome Measures:
  • Overall Survival (OS) Time in Months for All Randomized Participants at Updated Survival Follow-up [ Time Frame: Randomization until July 2015, approximately 33 months ] [ Designated as safety issue: No ]
    OS was defined as the time between the date of randomization and the date of death from any cause. Participants were censored at the date they were last known to be alive. Median OS time was calculated using Kaplan-Meier (KM) method. Hazard ratio (HR) and the corresponding Confidence Interval (CI) were estimated in a stratified Cox proportional hazards model for distribution of OS in each randomized arm. Survival follow-up analysis occurred 7.4 months after Primary Endpoint was reached, representing a minimum OS follow-up time of 18.0 months.


Enrollment: 352
Study Start Date: September 2012
Estimated Study Completion Date: January 2017
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A: Nivolumab
Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
Biological: Nivolumab
Other Name: BMS-936558
Experimental: Arm B: Docetaxel
Docetaxel 75 mg/m2 solution intravenously every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
Drug: Docetaxel
Other Name: Taxotere®

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Men and women ≥18 years of age
  • Subjects with histologically or cytologically-documented squamous cell NSCLC who present with Stage IIIB/IV disease or with recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection or definitive chemoradiation therapy for locally advanced disease)
  • Disease recurrence or progression during/after one prior platinum doublet-based chemotherapy regimen for advanced or metastatic disease
  • Measurable disease by computed tomography (CT)/Magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤1
  • A formalin fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides of tumor sample (archival or recent) must be available for biomarker evaluation. Specimens must be received by the central lab prior to randomization. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient

Exclusion Criteria:

  • Subjects with untreated central nervous system (CNS) metastases are excluded. Subjects are eligible if CNS metastases are treated and subjects are neurologically returned to baseline for at least 2 weeks prior to enrollment. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of ≤10 mg daily prednisone (or equivalent)
  • Subjects with carcinomatous meningitis
  • Subjects with active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
  • Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization
  • Prior therapy with anti-Programmed death-1 (PD-1), anti-Programmed cell death ligand 1 (PD-L1), anti-Programmed cell death ligand 2 (PD-L2), anti-CD137, or anti-Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
  • Prior treatment on the first line study CA184104 first line NSCLC study
  • Prior treatment with Docetaxel
  • Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
  • Treatment with any investigational agent within 14 days of first administration of study treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01642004

  Hide Study Locations
Locations
United States, Arizona
Mayo Clinic Arizona
Scottsdale, Arizona, United States, 85259
United States, California
City Of Hope National Medical Center
Duarte, California, United States, 91010
United States, Connecticut
Yale University
New Haven, Connecticut, United States, 06520
United States, Florida
H. Lee Moffitt Cancer Center
Tampa, Florida, United States, 33612
United States, Georgia
Northwest Georgia Oncology Center, P.C.
Marietta, Georgia, United States, 30060
United States, Illinois
University Of Chicago Medical Center
Chicago, Illinois, United States, 60637
United States, Maryland
The Johns Hopkins University
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, New York
Winthrop University Hospital
Mineola, New York, United States, 11501
Columbia University Medical Center
New York, New York, United States, 10032
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Ohio
Oncology Hematology Care
Cincinnati, Ohio, United States, 45242
United States, Pennsylvania
St Mary Medical Center
Langhorne, Pennsylvania, United States, 19047
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Guthrie Clinic, Ltd
Sayre, Pennsylvania, United States, 18840
United States, South Carolina
South Carolina Oncology Associates
Columbia, South Carolina, United States, 29210
United States, Tennessee
Chattanooga Oncology Hematology Associates
Chattanooga, Tennessee, United States, 37404
Tennessee Oncology, Pllc
Nashville, Tennessee, United States, 37203
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States, 37232
United States, Texas
University Of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390
The University Of Texas Md Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Washington
Swedish Cancer Institute
Seattle, Washington, United States, 98104
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109
United States, West Virginia
West Virginia University-Mbrcc
Morgantown, West Virginia, United States, 26506
Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina, 1431
Local Institution
Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina, CP1426ANZ
Local Institution
San Miguel De Tucuman, Tucuman, Argentina, CPT4000IAK
Local Institution
Buenos Aires, Argentina, 1417
Local Institution
Buenos Aires, Argentina, C1280AEB
Local Institution
Cordoba, Argentina, X5002AOQ
Australia, New South Wales
Local Institution
Wollongong, New South Wales, Australia, 2500
Australia, South Australia
Local Institution
Adelaide, South Australia, Australia, SA 5000
Local Institution
Elizabeth Vale, South Australia, Australia, 5112
Local Institution
Kurralta Park, South Australia, Australia, 5037
Australia, Victoria
Local Institution
East Bentleigh, Victoria, Australia, 3165
Austria
Local Institution
Linz, Austria, 4020
Local Institution
Salzburg, Austria, 5020
Local Institution
Vienna, Austria, 1130
Local Institution
Wels, Austria, 4600
Canada, Manitoba
Cancercare Manitoba
Winnipeg, Manitoba, Canada, R3E 0V9
Canada, Quebec
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Centre De Sante Et De Services Sociaux Rimouski Neigette
Rimouski, Quebec, Canada, G5L 5T1
Chile
Local Institution
Santiago, Metropolitana, Chile, 7600448
Local Institution
Recoleta, Santiago de Chile, Chile
Local Institution
Vi?a Del Mar, Valparaiso, Chile
Local Institution
Antofagasta, Chile, 240000
Local Institution
Santiago, Chile, 7630370
Czech Republic
Local Institution
Praha 8, Czech Republic, 180 81
France
Local Institution
Avignon Cedes 9, France, 84918
Local Institution
Caen, France, 14000
Local Institution
Dijon, France, 21000
Local Institution
La Roche Sur Yon Cedex 9, France, 85925
Local Institution
Lyon Cedex 08, France, 69373
Local Institution
Marseille Cedex 20, France, 13915
Local Institution
Pierre Benite, France, 69495
Local Institution
Rennes Cedex 9, France, 35033
Local Institution
Strasbourg, France, 67090
Local Institution
Toulouse, France, 31300
Germany
Local Institution
Bad Berka, Germany, 99437
Local Institution
Essen, Germany, 45122
Local Institution
Gerlingen, Germany, 70839
Local Institution
Grosshansdorf, Germany, 22927
Local Institution
Heidelberg, Germany, 69126
Local Institution
Koeln, Germany, 51109
Hungary
Local Institution
Budapest, Hungary, H-1121
Ireland
Local Institution
Dublin 8, Dublin, Ireland
Local Institution
Dublin 9, Dublin, Ireland
Italy
Local Institution
Bologna, Italy, 40138
Local Institution
Meldola (fc), Italy, 47014
Local Institution
Milano, Italy, 20133
Local Institution
Padova, Italy, 35128
Local Institution
Perugia, Italy, 06132
Local Institution
Ravenna, Italy, 48100
Local Institution
Siena, Italy, 53100
Mexico
Local Institution
Mexico City, Distrito Federal, Mexico, 14080
Local Institution
Mexico, Distrito Federal, Mexico, 06735
Local Institution
Leon, Guanajato, Guanajuato, Mexico, 37000
Local Institution
Hermosillo, Sonora, Mexico, 83280
Netherlands
Local Institution
Amsterdam, Netherlands, 1066 CX
Local Institution
Rotterdam, Netherlands, 3015 CE
Peru
Local Institution
Arequipa, Peru, 54
Local Institution
Lima, Peru, 34
Poland
Local Institution
Gdansk, Poland, 80-952
Local Institution
Krakow, Poland, 31-202
Local Institution
Olsztyn, Poland, 10-513
Local Institution
Szczecin, Poland, 70-891
Local Institution
Warszawa, Poland, 02-781
Romania
Local Institution
Bucuresti, Romania, 010976
Local Institution
Cluj-Napoca, Romania, 400352
Local Institution
Constanta, Romania, 900591
Local Institution
Craiova, Romania, 200385
Local Institution
Iasi, Romania, 700106
Local Institution
Timisoara, Romania, 300167
Russian Federation
Local Institution
Moscow, Russian Federation, 115 478
Local Institution
St. Petersburg, Russian Federation, 198255
Spain
Local Institution
Barakaldo, Spain, 48903
Local Institution
Barcelona, Spain, 08035
Local Institution
Madrid, Spain, 28040
Local Institution
Madrid, Spain, 28050
Local Institution
Sevilla, Spain, 41013
United Kingdom
Local Institution
Cottingham, East Yorkshire, United Kingdom, HU16 5JQ
Local Institution
Southampton, Hampshire, United Kingdom, SO16 6YD
Local Institution
Withington, Manchester, United Kingdom, M20 4BX
Local Institution
Sheffield, Yorkshire, United Kingdom, S10 2SJ
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01642004     History of Changes
Other Study ID Numbers: CA209-017  2011-004792-36 
Study First Received: July 9, 2012
Results First Received: February 19, 2016
Last Updated: March 16, 2016
Health Authority: Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Australia: Department of Health and Ageing Therapeutic Goods Administration
Austria: Federal Office for Safety in Health Care
Canada: Health Canada
Chile: Instituto de Salud Pública de Chile
Czech Republic: State Institute for Drug Control
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Hungary: National Institute of Pharmacy
Ireland: Irish Medicines Board
Italy: Ministry of Health
Mexico: Federal Commission for Sanitary Risks Protection
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Norway: Data Protection Authority
Norway: Directorate of Health
Peru: Instituto Nacional de Salud
Poland: National Institute of Medicines
Romania: National Medicines Agency
Russia: Ethics Committee
Russia: Ministry of Health of the Russian Federation
South Africa: Medicines Control Council
Spain: Spanish Agency of Medicines
Turkey: Ministry of Health
United States: Food and Drug Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Docetaxel
Nivolumab
Antibodies, Monoclonal
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on December 02, 2016